ArticleTobacco control2015
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation.
Article in Tobacco control, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Medical costs and quality-adjusted life years associated with smoking: a systematic review.BMC public health · 2016Pooled it
- Health Warning Labels for Smokeless Tobacco: The Impact of Graphic Images on Attention, Recall, and Craving.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2017Trial
- Variances in Smoking Expectancies Predict Moment-to-Moment Smoking Behaviors in Everyday Life.International journal of behavioral medicine · 2025Article
- Simulation Modeling for the Economic Evaluation of Population-Based Dietary Policies: A Systematic Scoping Review.Advances in nutrition (Bethesda, Md.) · 2021Article
- Article
- Research on Youth and Young Adult Tobacco Use, 2013-2018, From the Food and Drug Administration-National Institutes of Health Tobacco Centers of Regulatory Science.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Review
- Reassessing the importance of 'lost pleasure' associated with smoking cessation: implications for social welfare and policy.Tobacco control · 2018Article
- Smoking and Mortality: New Evidence from a Long Panel.International economic review · 2018Article
- Public health benefits from pictorial health warnings on US cigarette packs: a SimSmoke simulation.Tobacco control · 2017Article
- Regretting Ever Starting to Smoke: Results from a 2014 National Survey.International journal of environmental research and public health · 2017Article
- Public Preferences for the Use of Taxation and Labelling Policy Measures to Combat Obesity in Young Children in Australia.International journal of environmental research and public health · 2017Article
- Graphic Warning Labels and the Cost Savings from Reduced Smoking among Pregnant Women.International journal of environmental research and public health · 2017Article
- Economic analysis of the breast cancer screening program used by the UK NHS: should the program be maintained?Breast cancer (Dove Medical Press) · 2017Review
- The effects of maximising the UK's tobacco control score on inequalities in smoking prevalence and premature coronary heart disease mortality: a modelling study.BMC public health · 2016Article
- Cost Effectiveness of a Sugar-Sweetened Beverage Excise Tax in the U.S.American journal of preventive medicine · 2015Review
- Assessing tobacco regulation: moving beyond economists.Tobacco control · 2015Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Family Smoking Prevention and Tobacco Control Act of 2009 gave the Food and Drug Administration (FDA) regulatory authority over cigarettes and smokeless tobacco products and authorised it to assert jurisdiction over other tobacco products. As with other Federal agencies, FDA is required to assess the costs and benefits of its significant regulatory actions. To date, FDA has issued economic impact analyses of one proposed and one final rule requiring graphic warning labels (GWLs) on cigarette packaging and, most recently, of a proposed rule that would assert FDA's authority over tobacco products other than cigarettes and smokeless tobacco. Given the controversy over the FDA's approach to assessing net economic benefits in its proposed and final rules on GWLs and the importance of having economic impact analyses prepared in accordance with sound economic analysis, a group of prominent economists met in early 2014 to review that approach and, where indicated, to offer suggestions for an improved analysis. We concluded that the analysis of the impact of GWLs on smoking substantially underestimated the benefits and overestimated the costs, leading the FDA to substantially underestimate the net benefits of the GWLs. We hope that the FDA will find our evaluation useful in subsequent analyses, not only of GWLs but also of other regulations regarding tobacco products. Most of what we discuss applies to all instances of evaluating the costs and benefits of tobacco product regulation and, we believe, should be considered in FDA's future analyses of proposed rules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.